Regulation of aldosterone secretion by Ca(v)1.3 by Xie, CB et al.
Regulation of aldosterone secretion by Cav1.3.
Xie, CB; Shaikh, LH; Garg, S; Tanriver, G; Teo, AE; Zhou, J; Maniero, C; Zhao, W; Kang, S;
Silverman, RB; Azizan, EA; Brown, MJ
 
 
 
 
 
Article to be published in Scientific Reports: http://www.nature.com/srep/
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11789
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
1 
 
 1 
 2 
Regulation of aldosterone secretion by Cav1.3  3 
Catherine B Xie1†, Lalarukh Haris Shaikh1†, Sumedha Garg1, Gizem Tanriver1, Ada ED Teo1, 4 
Junhua Zhou1, Carmela Maniero1, Wanfeng Zhao2, Soosung Kang3, Richard B Silverman3, 5 
Elena AB Azizan1, 4*, Morris J Brown1*. 6 
 7 
 8 
1Clinical Pharmacology Unit, University of Cambridge, Box 110, Addenbrooke’s Hospital, 9 
Cambridge, CB2 2QQ, UK.  10 
2Human Research Tissue Bank, Cambridge University Hospitals NHS Foundation Trust, 11 
Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK.  12 
3Department of Chemistry, Chemistry of Life Processes Institute, and Center for Molecular 13 
Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208-3113, USA. 14 
4Department of Medicine, Faculty of Medicine, The National University of Malaysia (UKM) 15 
Medical Centre, Kuala Lumpur 56000, Malaysia. 16 
†,* These authors contributed equally to this work. 17 
 18 
 19 
Corresponding author: Professor Morris J. Brown1 20 
Tel: +44 (0)2078 823901; email: morris.brown@qmul.ac.uk 21 
22 
2 
 
Abstract 1 
Aldosterone-producing adenomas (APAs) vary in phenotype and genotype. Zona 2 
glomerulosa (ZG)-like APAs frequently have mutations of an L-type calcium channel (LTCC) 3 
CaV1.3. Using a novel antagonist of CaV1.3, compound 8, we investigated the role of CaV1.3 4 
on steroidogenesis in the human adrenocortical cell line, H295R, and in primary human 5 
adrenal cells. This investigational drug was compared with the common antihypertensive 6 
drug nifedipine, which has 4.5-fold selectivity for the vascular LTCC, CaV1.2, over CaV1.3. In 7 
H295R cells transfected with wild-type or mutant CaV1.3 channels, the latter produced more 8 
aldosterone than wild-type, which was ameliorated by 100 µM of compound 8. In primary 9 
adrenal and non-transfected H295R cells, compound 8 decreased aldosterone production 10 
similar to high concentration of nifedipine (100 µM). Selective CaV1.3 blockade may offer a 11 
novel way of treating primary hyperaldosteronism, which avoids the vascular side effects of 12 
CaV1.2-blockade, and provides targeted treatment for ZG-like APAs with mutations of CaV1.3. 13 
14 
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Aldosterone-producing adenomas (APAs), which arise from the adrenal cortex, are one of 1 
the most common curable causes of hypertension1-3. They account for approximately half of 2 
primary aldosteronism, which is estimated to be present in 5-13 % of all hypertensive 3 
patients, and in at least 20 % of patients with resistant hypertension4. However, it is likely 4 
that fewer than 10 % of APAs are ever diagnosed; and fewer still are removed in time to cure 5 
hypertension and prevent resistance to effective drug treatment2,5. 6 
 7 
We previously reported somatic gain-of-function mutations in two genes that regulate Na+, 8 
K+ and Ca2+ transport in APAs with a zona glomerulosa (ZG)-like phenotype6. Whole exome 9 
sequencing of small-cell APAs with a ZG-like gene expression profile found five out of ten to 10 
harbour one of four different somatic mutations in the voltage dependent L-type Ca2+ 11 
channel, CaV1.3 (encoded by the gene CACNA1D). These four substitution mutations, V259D, 12 
G403R, I750M, and P1336R, cluster around the Ca2+ pore between the S5 and S6 domains 13 
that line the inner pore surface. The mutations occur in conserved sites within functional 14 
domains such as the voltage-sensing domain to the pore (V259D and P1336R) and the 15 
channel activation gate (G403R and I750M)6. The G403R and I750M mutations were 16 
simultaneously reported as rare de novo germline mutations presenting at birth, together 17 
with several patients having somatic mutations of the same residues in sporadic APAs7. Our 18 
own replication sequencing revealed three further mutations, and sequencing of APAs in a 19 
large European consortium has now identified a total of 19 somatic mutations in or near one 20 
of the four Ca2+ channel pore-forming domains 6,8. Patch clamping of HEK293 cells has shown 21 
that at least 6 of the 19 mutations affect the Cav1.3 channel function and allow for increased 22 
Ca2+ influx through either shifting voltage-dependent activation towards more negative 23 
voltages, decelerating inactivation, and/or increasing currents through a higher open 24 
channel probability 6,9.  25 
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The current medical treatment of primary hyperaldosteronism is blockade of the 1 
mineralocorticoid receptor, which can lead to an increase in aldosterone secretion10. 2 
Therefore, blockade of calcium entry through selective antagonism of CaV1.3 might present a 3 
valuable therapeutic target. We therefore aimed to investigate whether CaV1.3 mutations 4 
cause the postulated increase in aldosterone secretion from human adrenocortical cells, and 5 
whether blockade of calcium entry reverses this. We studied the potential value of this 6 
target using 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione 7 
(compound 8), which was found to be more than 600 times more selective for CaV1.3 than 8 
CaV1.211. Nifedipine, a common antihypertensive drug, was used in comparison as a non-9 
selective, or slightly CaV1.2 selective antagonist of L-type calcium channels (IC50=0.016μM)12-10 
14. We also undertook immunohistochemistry of normal human adrenals, and APAs, in order 11 
to determine whether CaV1.3 is a ZG-selective LTCC and whether blockade may have greater 12 
expected effect on aldosterone secretion from APAs than from normal adrenal. 13 
 14 
To study the role of CaV1.3 on aldosterone secretion, we first investigated the substitution 15 
mutations near the voltage-sensing domain, P1336R and V259D, on 24-h aldosterone 16 
production in transiently transfected H295R cells to find if the different changes seen in our 17 
electrophysiology data translated to changes in aldosterone secretion6. We then contrasted 18 
the aldosterone secretion of cells transfected with mutant CaV1.3 channels to those 19 
transfected with wild-type CaV1.3 channel in the presence of compound 8 or nifedipine to 20 
study if blockade of calcium entry affects APAs with a CaV1.3 mutation differently. 21 
Transfection of H295R cells with exogenous CaV1.3 was performed with β3 and α2δ accessory 22 
subunits, the subunits we used previously to show gain-of function effects of the mutations 23 
on Ca2+ currents6. As transfected channels and subunits do not necessarily emulate in vivo 24 
expression, we also tested the effect of compound 8 and nifedipine on endogenous CaV1.3 25 
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present in H295R cells and primary adrenal cells acquired from adrenals containing an APA 1 
(both tumour and adjacent normal adrenal tissues).  2 
 3 
Results 4 
CaV1.3 mutations and compound 8 alter aldosterone production 5 
Transfection of H295R cells with CaV1.3 mutants P1336R and V259D caused a 2.4+0.2 6 
(P=0.0004) and 2.1+0.2 (P=0.002) fold increase, respectively, in basal aldosterone production 7 
compared to wild-type transfected H295R cells (Fig. 1a) and similarly in angiotensin II 8 
stimulated aldosterone production (Supplementary Fig. 1).  9 
 10 
Exposure of H295R cells transfected with wild-type CaV1.3 to low concentration (1 µM) of 11 
compound 8 almost doubled aldosterone secretion (P=0.007), whereas high concentration 12 
(100 µM) of compound 8 decreased aldosterone production to 35+0.1% of basal level 13 
(P=0.003, Fig. 1b) 14 
 15 
Effect of calcium blockade on CaV1.3 genotypes 16 
In cells transiently transfected with wild-type, P1336R, or V259D CaV1.3, there was a similar 17 
biphasic effect of compound 8 on aldosterone secretion from the mutant P1336R cells, as 18 
that seen in wild-type CaV1.3. In mutant V259D cells, compound 8 was inhibitory only at 100 19 
µM (Fig. 2a). Using the same protocol as for compound 8, the inhibitory effect of nifedipine 20 
on aldosterone secretion from CaV1.3 transfected H295R cells was determined. In wild-type 21 
CaV1.3 transfected cells, after treatment with 1 μM, 10 μM or 100 μM nifedipine, a 35+12 % 22 
decrease of aldosterone secretion was observed only at the highest concentration of 23 
nifedipine interrogated (100 μM)(P=0.0001, Fig. 2b) a considerable excess of its Ki for CaV1.2 24 
(IC50=0.016 μM)12,13. In P1336R and V259D transfected cells, despite the increased 25 
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aldosterone secretion compared to that of wild-type cells (as seen at 0 μM), the presence of 1 
high concentration of nifedipine (100 μM) decreased aldosterone production similarly across 2 
all genotypes (Fig. 2b).  3 
 4 
In non-transfected H295R cells (with only endogenous CaV1.3 and endogenous CaV1.3 5 
accessory subunits present), compound 8 and nifedipine, 1-100 μM, decreased basal 6 
aldosterone secretion (Fig. 2c).  7 
 8 
Compound 8 decreases aldosterone production in primary human adrenal cells  9 
In primary human adrenal cells cultured from the normal adjacent adrenals of patients with 10 
an APA, 10 and 100 μM of compound 8 inhibited aldosterone production by 35+10 and 11 
43+11 %, respectively (P<0.05; Fig. 3a). Cortisol secretion was also decreased to 72+1 and 12 
50+4 % of basal level, respectively (P<0.05; Supplementary Fig. 2). As for nifedipine, effect 13 
on aldosterone production was varied - not all cell cultures from the different patients 14 
showed a reduction, even at the high concentration of 100 µM (Fig. 3b). 15 
 16 
In APA cells, with increasing concentrations of 1, 10 and 100 μM, both compound 8 and 17 
nifedipine showed a dose dependent decrease in aldosterone production, to a minimum 18 
average of 54±2 and 43±13 % of basal level, respectively (P<0.005; Fig. 3c & d).  19 
 20 
 21 
Localization of CaV1.3 in adrenals containing an APA 22 
In sections of adjacent normal adrenal, that were adjacent to an APA or pheochromocytoma, 23 
CaV1.3 was detected in the ZG and the zona reticularis (ZR) (Fig. 4a). Only in ZG were 24 
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juxtanuclear accumulation seen (as shown in the zoomed image), as ZR staining was mainly 1 
cytoplasmic (Fig. 4a). Exogenous CaV1.3 in H295R transfected cells had mainly membranous 2 
expression (Supplementary Fig. 3). 3 
 4 
In APAs, different patterns of CaV1.3 expression were observed. CaV1.3 was expressed at the 5 
cell membrane, cytoplasmic, at the edge of cell clusters, or sparsely, or not at all (Fig. 4b and 6 
Supplementary Fig. 4). 7 
 8 
Discussion 9 
We previously reported that somatic mutation of Cav1.3 is present in a subset of APAs, 10 
distinguished by several features resembling normal ZG6. In a large multi-centre study of 474 11 
APAs, the frequency of Cav1.3 mutation was estimated to be 9.3 %8.  Although no particular 12 
histological phenotype was found in the multi-centre study 8, one centre within the study did 13 
subsequently report that of their 71 APAs, Cav1.3 mutant APAs (3 of 71) were composed 14 
mainly of zona glomerulosa-like cells15. Thus the current approximation could be a 15 
substantial underestimation since (a) half of our selected ZG-like APAs that were exome 16 
sequenced had a Cav1.3 mutation6; and (b) our experience that such tumours are frequently 17 
too small to be detected by conventional adrenal imaging. We therefore wished to show 18 
whether the mutations are likely to increase aldosterone production, rather than trigger 19 
development of the adenoma, and whether this increase could be reversed by blockade of 20 
calcium entry. As few APAs are diagnosed in time to offer high likelihood of surgical cure 21 
from hypertension, and the increased recognition of aldosterone morbidity, a need arises for 22 
novel therapies that suppress aldosterone production, and lack the adverse effects of 23 
aldosterone receptor blockade and other less specific therapies for hypertension.  24 
 25 
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Herein we report that the two CaV1.3 mutations studied, selected for having different 1 
electrophysiological effects6, do increase aldosterone secretion of transfected human 2 
adrenocortical cells (Fig. 1). Furthermore, calcium blockade using compound 8, an 3 
investigational CaV1.3 inhibitor, and nifedipine, a non-selective L-type calcium channel 4 
inhibitor, reversed the increase (Fig. 2). The inhibition of aldosterone secretion was seen in 5 
the presence of the highest concentration of compound 8 interrogated in this study (100 6 
µM) in H295R cells transfected with CaV1.3 mutants (Fig. 2); whereas in non-transfected 7 
H295R cells and primary adrenal cells, inhibition of aldosterone secretion could be seen at 8 
lower concentrations (1 and 10 µM) (Fig. 2c & Fig. 3d). We also postulate that regardless of 9 
whether a given APA has a somatic mutation of CaV1.3, the channel is often more active than 10 
in normal ZG cells, where immunohistochemistry suggests CaV1.3 is mainly internalised (Fig. 11 
4).  12 
 13 
Compound 8 was interrogated in this study as it was found to be the most selective CaV1.3 14 
antagonist among 60,480 commercial compounds and a few hundred non-commercial 15 
compounds (Silverman lab) tested for efficacy in blocking Cav1.3 or Cav1.2 in stably 16 
transfected HEK293 cells. Compound 8 was reported to inhibit CaV1.3 >600-fold more 17 
potently than CaV1.211. Subsequent studies have questioned this degree of selectivity, and 18 
even whether compound 8 is an agonist or antagonist16, 17. Nevertheless, it is well known 19 
that the effects of L-type Ca2+ channel blockade can differ among tissues depending on 20 
factors such as resting membrane potential18. Consequently, the hyperpolarisation of 21 
adrenocortical cells may have enhanced our ability to detect an antagonist effect of 22 
compound 8. Further, we may have fortuitously selected the CACNB isoform which 23 
maximises compound 8 selectivity, namely CACNB3 (encoding for the β3 subunit). In 24 
subsequent analysis, however, we found CACNB2 to be the predominant isoform in human 25 
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adrenal, indeed being one of the genes most up-regulated in ZG compared to zona 1 
fasciculata (ZF)19. Thus, for the pharmacological responses of the different mutations to be 2 
legitimately compared, a better CaV1.3 antagonist than Compound 8 is needed. Future 3 
antagonists should be developed not only based on its selectivity for CaV1.3 but also on its 4 
functionality with the prevalent accessory subunits in the human adrenal. 5 
 6 
In our cells transfected with exogenous CaV1.3, the stimulatory effect of apparent low dose 7 
calcium blockade on aldosterone secretion was observed only for Compound 8, but not 8 
nifedipine. This increase in aldosterone secretion could have been due to low dose 9 
compound 8 behaving as a channel activator16; but toxicity (and hence leakage of 10 
aldosterone) due to high calcium influx in transfected H295R cells cannot be dismissed, since 11 
no stimulation of aldosterone secretion was seen in untransfected cells (Fig 2c). The 12 
limitation of our expression Cav1.3 model, however, was that the cell line we used, H295R 13 
cells, express a mixture of endogenous Cav1.2 and Cav1.3 whereas primary human ZG cells 14 
express mainly Cav1.319,20. Moreover, the immortalised H295R cells were not a perfect 15 
model for primary aldosteronism as other adrenal corticosteroids are secreted21. This cell 16 
line was used mainly due to the ease of transfecting exogenous mutant CaV1.3. Hence, to 17 
supplement our transfection experiments, not only was compound 8 also studied in un-18 
transfected H295R cells, but also in primary adrenal cells (of which we have a limited 19 
supply), to support endogenous CaV1.3 role in aldosterone regulation. To note, as we did not 20 
find a linear relationship between increase in aldosterone production and amount of 21 
transfected constructs, no correction for transfection efficiency whether by Western blots or 22 
qPCR was performed. Transfection rates of exogenous CaV1.3 were confirmed as similar 23 
visually, using its GFP-tag.  24 
 25 
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Previous studies have shown a number of dihydropyridines to reduce aldosterone secretion 1 
from adrenocortical cells22. We chose nifedipine as a comparator because of experience with 2 
its use in patients, in whom it was the first dihydropyridine to be used23-25, and also because 3 
of its modest Cav1.2 selectivity. Nifedipine is expected to exert its Cav1.2 blockade at 4 
concentrations around 4.45nM14. At the lowest concentration of nifedipine that we had 5 
interrogated (1 µM), a concentration which should have easily blocked CaV1.2, only some 6 
inhibition of aldosterone could be seen in non-transfected H295R and primary adrenal cells 7 
and none at all in H295R cells transfected with CaV1.3 mutants (Fig. 2 & Fig. 3). The shallow 8 
concentration-response curves are consistent with blockade of different sites at low and 9 
high concentrations (Fig. 2 & 3). Dihydropyridines sometimes cause substantial reductions in 10 
plasma aldosterone in patients with primary aldosteronism26. However this is not the 11 
predominant response at usual clinical doses, and increasing the dose to the presumed 12 
Cav1.3-blocking range is precluded by the vascular side effects, particularly peripheral 13 
edema25,27.  14 
 15 
The potential attraction of selective CaV1.3 blockade is that such a drug can be used at a 16 
dose which achieves substantial suppression of aldosterone secretion, without the vascular 17 
side effects of currently used L-type Ca2+ blockers25,27. Previously, a T-type Ca2+ channel 18 
blocker, mibefradil, was introduced whose reduction in aldosterone secretion was among 19 
the theoretical advantages over L-type Ca2+ blockade28; however the drug was withdrawn 20 
due to reports of dangerous and even fatal interactions with other drugs  and was later 21 
found to cause serious effects on QTc29. In vitro studies at least, have shown that single 22 
blockade of either L-type or T-type Ca2+ channels can decrease aldosterone production, even 23 
though the influx of Ca2+ in the ZG is thought to be mediated by both channels28,30-32. While 24 
there has also been considerable attempt to develop inhibitors of aldosterone synthase as a 25 
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therapeutic class33, these have foundered on the challenge of developing a drug, which 1 
inhibits aldosterone synthase, without effect on the 95% homologous enzyme catalysing 2 
cortisol synthesis (encoded by the gene CYP11B1). By contrast, the homology between 3 
Cav1.2 and Cav1.3 is only 75%34. Thus, even though compound 8 itself may not be the ideal 4 
drug candidate to progress for treatment of hyperaldosteronism, there are a number of sites 5 
outside the dihydropyridine-binding site where Cav1.2 and Cav1.3 differ sufficiently to 6 
suggest that selective blockade is achievable. 7 
 8 
Three drugs do have clinical efficacy in patients with primary aldosteronism: spironolactone, 9 
eplerenone and amiloride35,36. However, the efficacy of the latter two is modest, and the use 10 
of spironolactone is severely limited in men by the anti-androgenic effects of higher 11 
doses37,38. All three drugs cause substantial increases in plasma aldosterone secretion, 12 
probably secondary to the rise in plasma K+, and there is some concern whether aldosterone 13 
could have adverse vascular effects through a non-canonical aldosterone receptor39,40. 14 
Although no evidence exists in humans, there is an additional theoretical benefit from 15 
blocking aldosterone synthesis rather than response – that such a drug could cause 16 
involution of aldosterone-producing cells. This is suggested by the observation that genetic 17 
deletion of the enzyme aldosterone synthase leads to apoptosis of the normal ZG cells41.  18 
 19 
In summary, we previously reported ZG-like APAs to have CaV1.3 mutations. In this study, we 20 
confirmed that CaV1.3 is localized to the human adrenal ZG. By blocking endogenous CaV1.3 21 
in primary human adrenal and transfecting mutant CaV1.3 in the human adrenocortical cell 22 
line, H295R, we have also confirmed that CaV1.3 plays a role in human adrenal 23 
steroidogenesis. Taken together, these discoveries suggest that CaV1.3 can provide a novel 24 
mechanism and target for regulating excess aldosterone secretion and may be a novel way 25 
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of treating hyperaldosteronism, especially those caused by ZG-like APAs with a CaV1.3 1 
mutation. Since non-selective or CaV1.2 selective dihydropyridines are dose-limited clinically 2 
by vascular effects, a selective CaV1.3 antagonist may be valuable for suppressing 3 
aldosterone secretion in some patients with aldosterone-dependent hypertension.  4 
 5 
Methods 6 
Cell culture experimentation 7 
H295R cells, were cultured in growth medium consisting of DMEM/Nutrient F-12 Ham 8 
supplemented with 10 % foetal bovine serum, 100 U of penicillin, 0.1 mg/mL streptomycin, 9 
0.4 mM L-glutamine and insulin-transferrin-sodium selenite medium (ITS) at 37°C in 5% CO2.  10 
For transient transfection, wild-type or mutant P1336R or V259D CaV1.3 GFP-tagged 11 
constructs were co-transfected together with constructs for β3 and α2δ auxiliary subunits of 12 
CaV1.3 into H295R cells using Amaxa Nucleofector kit R (Lonza, Germany) with 13 
electroporation program P20. The GFP-CaV1.3 wild-type and mutant vectors were obtained 14 
from our collaborators; Dr. Jöerg Striessnig’s group at University of Innsbruck Center for 15 
Chemistry and Biomedicine, Austria. These constructs were derived from the ‘long’ isoform 16 
of the CaV1.3 α1 pore-forming subunit, with isoform A of the alternatively spliced exon 8. 17 
Transfected cells were seeded into 24-well plates at 100, 000 cells per well in 0.5 mL of 18 
growth medium. At 24-h post-transfection, H295R cells were serum deprived in un-19 
supplemented DMEM/Nutrient F-12 Ham medium for 24-h. At 48-h post-transfection, the 20 
transfection efficiency was visualised and qualitatively quantified by fluorescence 21 
microscopy. Further experiments were performed on cells with 60-80% transfection 22 
efficiency. 23 
 24 
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For primary cell culture, adrenocortical cells were obtained from the adrenals of patients 1 
with Conn’s syndrome that had undergone adrenalectomy at Addenbrooke’s Hospital, 2 
Cambridge, UK (Supplementary Table 1). Local ethical approval and informed consent were 3 
obtained for each patient and the procedures followed were in accordance with institutional 4 
guidelines. After macroscopic identification of APA and adjacent normal adrenal by a trained 5 
histopathologist, tissue samples were placed in growth medium within 45 minutes of 6 
surgical excision. The APA and adjacent normal adrenal was then digested separately in 3.3 7 
mg/ml collagenase at 37 °C for 2h. Within a week of procurement, the primary human 8 
adrenocortical cells were then randomly seeded into 24-well plates at 50, 000 cells per well 9 
in 0.5 mL of growth medium and allowed to settle for a further 48-h before drug treatments 10 
were performed.  11 
 12 
Drug treatments with CaV1.3 selective antagonist, compound 8, and L-type calcium blocker, 13 
nifedipine 14 
Compound 8 and nifedipine (Sigma-Aldrich, UK) were reconstituted in DMSO to stock 15 
concentrations of 1, 10, and 100 mM. Stock concentrations were further diluted (1:1000) in 16 
sterile un-supplemented DMEM/Nutrient F-12 Ham for treatments.  17 
 18 
Transfected H295R cells were treated at 48-h post transfection (after 24-h of serum 19 
deprivation) with either vehicle or compound 8 or nifedipine in un-supplemented 20 
DMEM/Nutrient F-12 Ham medium in the presence of 10 nM angiotensin II. Supernatant and 21 
cells were harvested after 24-h incubation at 37°C. 22 
 23 
For non-transfected H295R cells, cells were seeded into 24-well plates at 100 000 cells per 24 
well in 0.5 mL of growth medium, serum deprived for 24-h, and treated with either vehicle, 25 
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compound 8 or nifedipine in un-supplemented DMEM/Nutrient F-12 Ham medium. 1 
Supernatant and H295R cells were harvested after 24-h incubation at 37°C. 2 
 3 
For primary human adrenal cells, APA and adjacent normal adrenal cells were serum 4 
deprived for 24-h, and treated with either vehicle or compound 8 or nifedipine in un-5 
supplemented DMEM/Nutrient F-12 Ham medium in the presence or absence of 10 nM 6 
angiotensin II. Supernatant and H295R cells were harvested after 24-h incubation at 37°C. 7 
 8 
Immunohistochemistry 9 
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded adrenal 10 
sections (4 μm) using an automated immunostainer with cover tile technology (Bond-III 11 
system, Leica Biosystems). The commercial antibody of CACNA1D, clone N38/8 (UC 12 
Davis/NIH NeuroMab Facility; 1:500 dilution), was used as the primary antibody. Negative 13 
control experiments, in which the primary antibody was omitted, resulted in a complete 14 
absence of staining. Images were captured using a standard bright-field microscope, a U-15 
TV1-X digital camera and CellD software (Olympus UK). 16 
 17 
Confocal Imaging 18 
H295R cells were cultured in complete media on sterilised and poly L-lysine coated cover-19 
slips at the density of 105cells/well in 12-well cell-culture plate for 24h. Cells were serum-20 
starved overnight before transfection. Serum-free media was replaced with antibiotic-free 21 
serum-containing media at the time of transfection with Lipofectamine 3000 transfection 22 
reagent (Life Technologies). Cells were co-transfected with GFP-tagged Cav1.3 WT, β3 & α2δ 23 
constructs according to manufacturer’s instructions. 48h later plasma membranes of cells 24 
were stained with 2ug/ml Wheat Germ Agglutinin, Alexa Fluor® 633 Conjugate (W21404, Life 25 
15 
 
Technologies) in complete media for 10min at 37°C. Cells were washed twice with PBS (5min 1 
each), followed by fixing with 4% paraformaldehyde and permeabilisation with 1% trition-2 
X100 (PBST), 10min each at room temperature. Cells were incubated with blocking buffer 3 
(3% BSA in PBS) for 1h at room temperature and overnight with α-Cav1.3 (1:500, Clone 4 
N38/8, NeuroMab) in 3% BSA-PBST. Goat anti-mouse IgG, Alexa Fluor® 568 Conjugate 5 
(A11004, Life Technologies) was used as secondary antibody at 1:1000 dilution in 3%BSA-6 
PBST for 1-h at room temperature. Finally cells were washed thrice in PBST and cover-slips 7 
were mounted on slides using VECTASHIELD Antifade Mounting Medium with DAPI (H-1200, 8 
Vector Laboratories). Confocal images were taken using Zeiss LSM510 Meta confocal 9 
microscope and analysed using Zen 2011 software. 10 
 11 
Aldosterone concentration measurements 12 
Aldosterone concentration was quantitatively measured using three methods due to 13 
availability of the kits; Coat-A-Count® Aldosterone (Siemens Medical Solutions, USA), a125I 14 
solid-phase radioimmunoassay and after the discontinuation of this kit, an ELISA method 15 
adapted from researchers in Gomez-Sanchez’s group and finally a commercially available 16 
Homogenous Time Resolved Fluorescence Resonance Energy Transfer (HTR-FRET) assay from 17 
Cisbio Bioassays, France (used according to manufacturer’s instructions). ELISA was carried 18 
out using a selective validated aldosterone monoclonal antibody gifted to us and produced 19 
by Gomez-Sanchez’s lab, USA42. The aldosterone concentrations from transfected H295R 20 
cells were normalized to total cell protein, which was determined by performing the 21 
bicinchoninic acid (BCA) protein assay (Pierce Biotechnology, USA). 22 
 23 
Statistical analysis 24 
16 
 
Experiments were performed with vehicle/plasmid controls where appropriate. Each 1 
experiment was performed with biological replicates and the averages were calculated. 2 
Aldosterone measurements are expressed as a ratio of basal (control) for each experiment. 3 
Results are shown as mean values ± SEM of separate experiments/transfections unless 4 
stated otherwise. Statistical analysis, two-tailed Student's t-tests or analysis of variance, was 5 
performed as indicated using the standard statistical software, Prism 6 (GraphPad Software, 6 
Inc).  7 
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Fig.1: CaV1.3 mutations and compound 8 alter aldosterone production 1 
Comparison of stimulated aldosterone production in (a) wild-type (WT), P1336R, and 2 
V259D CaV1.3 transfected H295R cells (n=5) and in (b) different concentration of 3 
compound 8 on WT H295R cells (n=3).  4 
Student t-test was used to calculate significance. **P<0.01 and ***P<0.001, compared to 5 
baseline (Wild-type or 0 M compound 8). 6 
The n value represents number of separate experiment/transfection performed. Each 7 
experiment/transfection had 6 biological replicates. Aldosterone results shown here were 8 
measured by RIA method and are relative to basal level (Wild-type or 0 M compound 8). 9 
21 
 
Fig.2: Effect of compound 8 on aldosterone production of different CaV1.3 genotype 1 
(a) Stimulated aldosterone secretion (n=3) in the presence of compound 8 and (b) 2 
stimulated aldosterone secretion in the presence of nifedipine (n=3) on WT, P1336R 3 
and V259D CaV1.3 transfected H295R cells. There was a similar biphasic effect of 4 
compound 8 on aldosterone secretion from the mutant P1336R cells (P=0.02; 5 
Student’s t-test), as that seen in wild-type CaV1.3, but not so in mutant V259D cells or 6 
when transfected cells were treated with nifedipine. (c) Comparison of basal 7 
aldosterone production of non-transfected H295R cells in the presence of 0-100 µM of 8 
compound 8 or nifedipine (n=3). 9 
Two-way ANOVA was used to calculate overall significance. Table of P-values shows 10 
significance of mutation status (Mutation), concentration of treatment (Concentration), and 11 
type of treatment (Drug), on aldosterone production. The n value represents number of 12 
separate experiment/transfection performed. Each experiment/transfection had 6 biological 13 
replicates. Aldosterone was measured by RIA (a & b) or RIA and HTR-FRET (c) method. 14 
Results of both methods are relative to basal level (Wild-type or 0 M of treatment).15 
22 
 
Fig.3: Compound 8 decreases aldosterone production in primary human adrenal cells  1 
Aldosterone secretion of (a & b) normal primary adrenal cells or (c & d) aldosterone-2 
producing adenomas (APAs) in the presence of compound 8 (a & c) or nifedipine (b & d). 3 
Dose response curve between 0-100 μM of compound 8 on (a) normal primary adrenal cells 4 
(n=4) and (c) APA cells (n=3), and nifedipine on (b) normal primary adrenal cells (n=3) and (d) 5 
APA cells (n=3).  6 
Two-way ANOVA was used to calculate overall significance. Table of P-values shows 7 
significance of patient differences (Patient variability) and concentration of treatment 8 
(Concentration) on aldosterone production. The n value represents number of individual 9 
patient samples used for each experiment. Each concentration was replicated 2-12 times 10 
within each individual patient samples (which depended on quantity of primary cells 11 
available). Aldosterone results shown here are relative to 0 M of treatment.  12 
Numbers 181, 182, 184, 187, 196, and 221 represent individual patient ID. Clinical data for 13 
these patients is provided in Supplementary Table 1. Primary cell cultures from patients 181, 14 
182, and 184 were performed in the absence of angiotensin II (seen as solid bars) whereas 15 
primary cell cultures 187, 196, and 221 were stimulated with 10 nM angiotensin II (seen as 16 
hatched bars). Aldosterone was measured by RIA and ELISA method.  17 
18 
23 
 
Figure 4: Localization of CaV1.3 in human adrenals 1 
a) Immunohistochemistry (IHC) of CaV1.3 on formalin-fixed paraffin-embedded (FFPE) 2 
adrenal sections localized the channel to the zona glomerulosa (ZG) and zona reticularis 3 
(ZR) of the adrenals. In the ZG, cytoplasmic and juxtanuclear accumulation of CaV1.3 was 4 
observed whereas in the ZR, staining was mainly cytoplasmic.  5 
Picture is representative of 12 normal adjacent adrenal glands, 3 from patients with a 6 
phaeochromocytoma and 9 from patients with an aldosterone-producing adenoma (APA). 7 
C, capsule; G, zona glomerulosa; F, zona fasciculata; R, zona reticularis; M, adrenal 8 
medulla. 9 
b) CaV1.3 expression in APA cells. IHC of CaV1.3 on FFPE adrenal sections were 10 
performed on three different types of APAs: (i-iii) ZG-like (low nucleus to cytoplasm ratio) 11 
APAs without a CaV1.3 mutation, (iv-vi) APAs with a CaV1.3 mutation, and (vii-ix) APAs 12 
with a KCNJ5 mutation. Immunostaining reveals a mixture of cytoplasm and membranous 13 
sublocalization in APA cells.  14 




